prakash nallathamby retweeted
Engineered antibodies may produce remissions and offer safety benefits over cell therapies that have killed autoimmune patients.
Learn more: scim.ag/4zAmqeR
prakash nallathamby retweeted
For readers interested in mRNA therapeutics, including mRNA-based cancer vaccines as well as a range of other types such as in vivo CAR-T therapies and genome editors, here's a recent Review nature.com/articles/s41573-0…
rdcu.be/FAnmLC17TFfa
prakash nallathamby retweeted
Cancer vaccine development gets complicated
nature.com/articles/d41573-0…
Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than answers about the future of cancer vaccines.
prakash nallathamby retweeted
A new test developed by Notre Dame researchers can detect early markers of pancreatic cancer, glioblastoma, colorectal cancer, and Alzheimer’s disease: go.nd.edu/4145bf
prakash nallathamby retweeted
A microchip-based DNA synthesis method enables scalable production of complex DNA constructs go.nature.com/3VKimYk
rdcu.be/tRkisNTdo5Va
prakash nallathamby retweeted
Stanford scientists have developed a revolutionary microscope called Interferometric Image Scanning Microscopy (iISM) that reveals the inner workings of living cells in real time at 120-nanometer resolution—completely without the fluorescent labels that can interfere with cell behavior!
sciencedaily.com/releases/20…
#Microscopy #CellBiology #Biotechnology #Stanford #microscope #ScienceNews #Innovation
prakash nallathamby retweeted
If you’ve been wondering what the AI bio chatter is all about, this piece from the A16Z Bio+Health team is a great overview. I like this chart in particular, gives a great sense of where/how AI is impacting the drug discovery and pre clinical development stages:
prakash nallathamby retweeted
I'm only going to say this TWICE.
Peter Lynch says a PEG ratio below 1 is undervalued.
Here are 6 of the biggest companies in the world trading below it:
1/6 $GOOGL - 0.2x PEG
prakash nallathamby retweeted
New in Nature Cancer: CAR-T cells with a radiation-inducible promoter, so TNF is released only where the beam goes. High TNF in the tumor, none in serum.
doi.org/10.1038/s43018-026-0…
I was lucky to be part of this team. I learned a great deal from them and it was a valuable time for me.
CAR-T plus RT is still not a familiar combination in our field, but I think it could become another weapon for rad onc. We already know RT has systemic effects, immune mediated but hard to predict. This is a different trigger: the beam switches on a gene in a cell we built. Putting dose exactly where we want it is the one thing we are good at. This is one way to use that precision for something other than local control.
Congrats to Elham, Ainhoa and @rweichselbaum. Years of work finally landed. Always rooting for what comes out of that lab next, and I will be waiting for it.
prakash nallathamby retweeted
Today, SpaceX permanently altered the balance of global economics, politics, and modern warfare.
After deploying 26 next-gen Starlink V3 satellites across 14 orbits, Ship 42 survived Mach 25+ reentry and landed cleanly inside Mechazilla’s arms at Starbase.
Here is why every finance minister, regulator, and defense ministry on Earth just woke up to a new reality:
1. Full upper-stage reuse drops orbital launch costs toward fuel-and-maintenance levels. Combined with Terafab’s captive silicon and SpaceX’s 100 GW HJT solar orders for Starmind, Musk can now deploy gigawatt-scale orbital AI data centers and global broadband faster and cheaper than terrestrial hyperscalers stuck in 5-year utility queues.
2. A fully reusable Starship deploying 26+ V3 satellites per flight creates an un-censorable, direct-to-cell global communications and compute layer that bypasses national telecom monopolies, undersea cable chokepoints, and local regulatory vetoes.
3. Modern conflict is now defined by resilient LEO satellite meshes, hypersonic missile tracking, and rapid logistics. Today’s catch proves the U.S. has an industrial heavy-lift engine capable of replenishing entire defense constellations (Starshield) in days—and eventually dropping 100+ tons of military cargo anywhere on Earth in under 45 minutes.
History will mark November 14, 2026 as the day space stopped being an exploration frontier and became the decisive high ground of global power.
If you want to know why the Pentagon is watching Ship 42’s reentry trajectory today just as closely as NASA, look at what full Starship reusability does to global military logistics.
Right now, moving 100 tons of heavy equipment across the planet requires aircraft carriers, overseas airbases, diplomatic overflight clearances, and days of transit time.
Once Starship proves repeatable tower-to-tower recovery:
> The U.S. military gains the ability to drop 100+ tons of cargo, autonomous drone swarms, or mobile defense grids anywhere on Earth in under 45 minutes, without asking a single neighboring country for airspace permission.
> Combined with SpaceX’s $100B second Starbase complex in Louisiana (designed for up to 10,000 launches a year), heavy orbital lift becomes a strategic deterrent on par with nuclear submarines.
I bet that within 3 years of Starship’s first successful upper-stage catch, every major geopolitical power will be forced to rewrite its defense doctrine around suborbital rapid response.
prakash nallathamby retweeted
When a US hospital hits you with a $4,200 summary bill for a basic 3-hour ER visit:
Dumb patient:
- Panics at the total
- Assumes the price is legally set in stone
- Calls to set up a $150/month payment plan
Smart patient: ↓↓
prakash nallathamby retweeted
> be me, reading a new paper about directed evolution in human B cells
> B cells naturally mutate antibody genes; called somatic hypermutation
> seems like a really good idea to "borrow" that machinery to evolve other types of proteins, too
> researchers put a gene into the B cells, add a short stretch of DNA upstream (to recruit the antibody-making proteins), and let the cells generate a bunch of mutations
> periodically sort the cells via flow cytometry to keep the best ones
> use this to make flu-antibody variants with 3x better binding
> no need to build and keep cloning a mutant library between every round
> start thinking about selecting for several useful properties at once, directly in human cells
> yeah, this seems really useful
> but wait
> feel like I’ve heard this idea before
> find a 2004 paper by Roger Tsien
> they did the exact same thing, using B cells to evolve new fluorescent proteins, 22 years ago
> (this is where mPlum and mRaspberry came from)
> why have I never heard of this?
> suddenly realize most things in biology actually came from somewhere else and most ideas are much older than people think
> Francis Crick was calling for control over neurons in Scientific American in 1979
> by 1999 he was explicitly saying we should use light as the signal
> optogenetics is 'invented' a few years later
> people say future laboratories are going to be fully automated
> Zymark said the same thing in the 1980s, and it never happened
> ideas in biology repeat themselves
prakash nallathamby retweeted
Cancer drug resistance as a temporal process: cell plasticity, adaptive buffering, signaling pathways and therapeutic interception
nature.com/articles/s41392-0…
prakash nallathamby retweeted
Molecular PET in lung cancer may reveal not only tumor location but also heterogeneity in targets such as EGFR, HER2, MET, and PD-L1 across metastases.
It could play an important role in future treatment selection, but its clinical benefit remains unproven.
lungcancerjournal.info/artic…
prakash nallathamby retweeted
This trial is of an oncolytic virus that encodes a novel TGFbeta receptor inhibitor that we developed in the lab. Super excited to see it change the lives of cancer patients!
See the preclinical paper here: rupress.org/jem/article/220/…
We're pleased to share that our STEALTH-001 clinical trial abstract was one of just two selected for the inaugural SITC Biotech Innovation Spotlight Award!
Thank you to Dr. Yana Najjar, our investigators, collaborators and patients.
#SITC2026 #CancerImmunotherapy
prakash nallathamby retweeted
Using spatial transcriptomics to train AI to analyze routine H&E slides.
Together with Celso Camilo's group, we just published a new paper introducing MOSAIC, a computer vision method that predicts gene expression from histology and uses those predictions to infer cell identity.
The key idea was to look beyond each cell’s individual morphology and incorporate its neighbors, using the surrounding cellular context to guide the prediction.
Paper here: nature.com/articles/s41598-0…
A pioneering therapy that edits genes inside a recipient’s body continues to be effective four years after treatment
go.nature.com/4sWfuXQ
prakash nallathamby retweeted
Be Jensen:
> Asian American Dishwasher at Dennys
> Founded $NVDA and pioneered GPU computing
> Took an extraordinary gamble in CUDA, despite the company close to bankruptcy risk.
> Bet paid off heavily, and Nvidia was there as the infrastructure for deep learning and generative AI.
> Spent last 33 years of his life growing $NVDA, and finally saw it become a $5T+ company
> Devoted his life to establishing American AI leadership
> Started having more influence on policies that Washington conflicted with
> Leaks and hit pieces happen all at once around midterms
> Washington tries to push out others like Lutnick that shared similar China stances to Jensen.
> Forced to resign by Taco Bell and NFL experience board members over unconfirmed Spy accusations + personal relationships.
> Huang's leadership then questioned by politicians that ask how $META makes money or how Wifi works.
> Slandered by US media that think because Mcdonalds did well under a CEO change, so can American semiconductors like $NVDA.
This feels like a horrible joke. Jensen Huang was the pinnacle of visionary tech CEOs and living the American dream.
Ousting Jensen Huang will go down as one of most consequential and darkest decisions in recent US history.































